title: [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
abstract: Androgen-independent progression invariably occurs following castration of patients with prostate cancer. Animal model data suggest that androgen resistance may result from adaptive cell survival mechanisms activated by androgen withdrawal. If this is true, then re-exposure to, or low levels of, androgens may suppress or downregulate these mechanisms. The objective of this study is to determine whether intermittent androgen suppression (IAS) delays the onset of nonandrogen-regulated PSA production in the LNCaP prostate tumour model, when compared to continuous androgen suppression (CAS). Serum PSA levels correlate highly with LNCaP tumour volume and decrease rapidly following castration; beginning 3-4 weeks post-castration LN CaP tumours become androgen-independent with respect to PSA gene expression and produce PSA in amounts similar to precastrate state. In this study, IAS-treated mice were implanted with testosterone pellets beginning two weeks post-castration; cycles of testosterone replacement for 1 week and withdrawal for 2 weeks were repeated until serum PSA levels no longer returned to baseline. IAS therapy prolonged time to androgen-independent PSA production 3-fold, from an average of 26 days in the CAS group to 77 days in the IAS group. Serum and LNCaP tumour mRNA PSA levels remained below precastrate levels by 60 days post-castration in 75% of the IAS group, while serum PSA in all mice in the CAS group exceeded precastrate PSA by 28 days post-castration. Following castration, serum PSA levels increased 9-fold faster with CAS compared to IAS therapy. Observations using IAS in the LNCaP tumour model suggest that the onset of androgen-independent PSA gene regulation is prolonged 3-fold, perhaps due to androgen-induced differentiation and/or downregulation of androgen-suppressed gene expression.
authors.affiliation: Department of Cancer Endocrinology, British Columbia Agency, Vancouver, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Gleave
authors.forename: N
authors.initials: N
authors.lastname: Santo
authors.forename: P S
authors.initials: PS
authors.lastname: Rennie
authors.forename: S L
authors.initials: SL
authors.lastname: Goldenberg
authors.forename: N
authors.initials: N
authors.lastname: Bruchovsky
authors.forename: L D
authors.initials: LD
authors.lastname: Sullivan
mesh_terms: D000728:Androgens / Q000096:biosynthesis*; D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000097:blood* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood* / Q000737:chemistry; D012333:RNA, Messenger / Q000096:biosynthesis
chemical_list: D000728:Androgens; D012333:RNA, Messenger; D017430:Prostate-Specific Antigen
vernacular_title: Echappement hormonal et hormonothérapie intermittente dans le modèle LN CaP de cancer prostatique humain.